Complement C1s inhibition with sutimlimab results in durable response in cold agglutinin disease: CARDINAL study 1-year interim follow-up results

• Alexander Roth,
• Wilma Barcellini,
• Shirley D’Sa,
• Yoshitaka Miyakawa,
• Catherine M. Broome,
• Marc Michel,
• David J. Kuter,
• Bernd Jilma,
• Tor Henrik Anderson Tvedt,
• Ilene C. Weitz,
• Parija Patel,
• Xiaoyu Jiang,
• Caroline Reuter,
• Jun Su,
• Frank Shafer,
• Michelle Lee,
• Sigbjorn Berentsen

Affiliations

Alexander Roth

Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen

Wilma Barcellini

Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan

Shirley D’Sa

UCLH Centre for Waldenstrom’s Macroglobulinemia and Related Conditions, University College London Hospitals NHS Foundation Trust, London

Yoshitaka Miyakawa

Thrombosis and Hemostasis Center, Saitama Medical University Hospital, Saitama

Catherine M. Broome

Division of Hematology, MedStar Georgetown University Hospital, Washington

Marc Michel

Henri-Mondor University Hospital, Assistance Publique-Hopitaux de Paris, UPEC, Creteil

David J. Kuter

Division of Hematology, Massachusetts General Hospital, Harvard Medical School, Boston

Bernd Jilma

Department of Clinical Pharmacology, Medical University of Vienna, Vienna

Tor Henrik Anderson Tvedt

Section for Hematology, Department of Medicine, Haukeland University Hospital, Bergen

Ilene C. Weitz

Keck School of Medicine of USC, Los Angeles, CA

Parija Patel

Sanofi, Cambridge

Xiaoyu Jiang

Sanofi, Cambridge

Caroline Reuter

Sanofi, Cambridge

Jun Su

Sanofi, Cambridge

Frank Shafer

Sanofi, Cambridge

Michelle Lee

Sanofi, Cambridge

Sigbjorn Berentsen

Department of Research and Innovation, Haugesund Hospital, Haugesund